Dova Pharmaceuticals (NASDAQ:DOVA) had its price objective hoisted by HC Wainwright from $39.00 to $45.00 in a research report released on Thursday, The Fly reports. HC Wainwright currently has a buy rating on the stock.

A number of other research analysts also recently issued reports on the company. JPMorgan Chase & Co. increased their price objective on Dova Pharmaceuticals from $13.00 to $15.00 and gave the stock an underweight rating in a report on Friday, July 12th. Wedbush assumed coverage on Dova Pharmaceuticals in a report on Wednesday, May 22nd. They set an outperform rating and a $19.00 price objective for the company. Evercore ISI upgraded Dova Pharmaceuticals from an in-line rating to an outperform rating and set a $15.00 price objective for the company in a report on Monday, July 1st. Zacks Investment Research upgraded Dova Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, September 13th. Finally, BidaskClub downgraded Dova Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Saturday, August 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Dova Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $25.43.

NASDAQ:DOVA opened at $15.10 on Thursday. The company has a current ratio of 5.64, a quick ratio of 5.37 and a debt-to-equity ratio of 0.41. Dova Pharmaceuticals has a 52-week low of $5.62 and a 52-week high of $24.72. The stock has a 50-day simple moving average of $15.39 and a 200 day simple moving average of $11.91.

Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.03). The firm had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.63 million. Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. As a group, analysts forecast that Dova Pharmaceuticals will post -2.44 earnings per share for the current fiscal year.

In related news, major shareholder Life Sciences Maste Perceptive purchased 427,209 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was purchased at an average cost of $13.35 per share, for a total transaction of $5,703,240.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Paul B. Manning purchased 28,062 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was bought at an average price of $15.87 per share, with a total value of $445,343.94. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 610,916 shares of company stock valued at $8,689,169 and sold 27,807 shares valued at $422,464. 60.30% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. Capital Investment Advisory Services LLC grew its stake in Dova Pharmaceuticals by 222.2% in the second quarter. Capital Investment Advisory Services LLC now owns 2,900 shares of the company’s stock valued at $45,000 after purchasing an additional 2,000 shares in the last quarter. Quantamental Technologies LLC grew its stake in Dova Pharmaceuticals by 1,100.0% in the second quarter. Quantamental Technologies LLC now owns 2,400 shares of the company’s stock valued at $34,000 after purchasing an additional 2,200 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Dova Pharmaceuticals by 22.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 13,300 shares of the company’s stock worth $336,000 after acquiring an additional 2,400 shares during the period. Doyle Wealth Management bought a new position in shares of Dova Pharmaceuticals during the 2nd quarter worth approximately $49,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Dova Pharmaceuticals by 6.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 67,386 shares of the company’s stock worth $951,000 after acquiring an additional 3,992 shares during the period. Hedge funds and other institutional investors own 32.18% of the company’s stock.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Featured Article: Asset Allocation and Your Retirement

The Fly

Analyst Recommendations for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.